Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
268.46
-2.56 (-0.94%)
At close: Mar 28, 2025, 4:00 PM
266.00
-2.46 (-0.92%)
After-hours: Mar 28, 2025, 7:58 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 319.27, with a low estimate of 220 and a high estimate of 500. The average target predicts an increase of 18.93% from the current stock price of 268.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock from 23 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 | 10 |
Buy | 7 | 7 | 7 | 8 | 8 | 9 |
Hold | 6 | 5 | 5 | 5 | 4 | 3 |
Sell | 0 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 23 | 23 | 23 | 24 | 23 | 23 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Hold → Buy Upgrades $280 → $328 | Hold → Buy | Upgrades | $280 → $328 | +22.18% | Mar 24, 2025 |
Citigroup | Citigroup | Strong Buy Maintains $338 → $351 | Strong Buy | Maintains | $338 → $351 | +30.75% | Mar 21, 2025 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $385 → $390 | Strong Buy | Maintains | $385 → $390 | +45.27% | Mar 21, 2025 |
RBC Capital | RBC Capital | Buy Maintains $310 → $330 | Buy | Maintains | $310 → $330 | +22.92% | Mar 21, 2025 |
Scotiabank | Scotiabank | Buy Maintains $300 → $338 | Buy | Maintains | $300 → $338 | +25.90% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
2.95B
from 2.25B
Increased by 31.04%
Revenue Next Year
3.64B
from 2.95B
Increased by 23.56%
EPS This Year
-1.67
from -2.18
EPS Next Year
1.03
from -1.67
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.6B | 4.3B | 5.9B | ||
Avg | 2.9B | 3.6B | 4.7B | ||
Low | 2.4B | 3.1B | 3.7B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 62.2% | 46.0% | 63.4% | ||
Avg | 31.0% | 23.6% | 28.1% | ||
Low | 7.9% | 5.6% | 0.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 1.13 | 6.47 | 10.82 | ||
Avg | -1.67 | 1.03 | 5.07 | ||
Low | -3.55 | -2.24 | 2.01 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 948.9% | ||
Avg | - | - | 391.4% | ||
Low | - | - | 94.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.